Amgen alliance 'evolution' of AstraZeneca's peer-to-peer deal model
This article was originally published in Scrip
Executive Summary
"We like these peer-to-peer collaborations, they are a good way to work," AstraZeneca's vice president of strategic partnering and business development, Shaun Grady, told Scrip. He was discussing this week's announcement that the Anglo-Swedish pharma has signed an agreement with Amgen to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio, including the Phase III-ready brodalumab (AMG827). The other four assets are in Phase I (scripintelligence.com, 3 April 2012).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.